RAS G12C Inhibitors: Three Birds with One Stone

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRAS mutations, particularly G12C, are common drivers in various cancers.
• Targeting KRAS G12C with covalent inhibitors has shown therapeutic promise.
• Understanding off-target binding is crucial for optimizing inhibitor efficacy and safety.

Purpose of the Study:

• To investigate the covalent binding profiles of different G12C inhibitors.
• To determine if G12C inhibitors can target other RAS isoforms, such as NRAS and HRAS.
• To identify potent inhibitors for NRAS G12C, a less explored oncogenic driver.

Main Methods:

• Comparative analysis of covalent binding of G12C inhibitors across KRAS, NRAS, and HRAS.
• Biochemical assays to assess inhibitor-protein interactions.
• In vitro studies to evaluate the potency of identified inhibitors.

Main Results:

• G12C inhibitors exhibit differential abilities to covalently bind to KRAS G12C, NRAS G12C, and HRAS G12C.
• Sotorasib demonstrates significant covalent binding to NRAS G12C.
• The study highlights the potential for broader RAS isoform inhibition by G12C-targeted drugs.

Conclusions:

• Differences in covalent binding capabilities among G12C inhibitors impact their target spectrum.
• Sotorasib is identified as a promising therapeutic candidate for NRAS G12C-driven cancers.
• Targeting multiple RAS isoforms may offer a more effective strategy for certain malignancies.